Platinum-resistant Ovarian Cancer Recruiting Phase 3 Trials for Pembrolizumab (DB09037)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

IndicationStatusPhase
DBCOND0068919 (Platinum-resistant Ovarian Cancer)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs